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HIGHLIGHTS 
• Recent therapeutic approaches for MS focus on CD20+ B cells yet emerging evidence indicates 
these approaches also target T cells.  
• EAE in animals is used to identify mechanisms and generate  therapies for translation to MS, a 
uniquely human disease. 
• The original assumption of the role of B cells was as a source of pathogenic antibodies yet many 
more functions have been revealed.  
 B cell therapies in EAE do not reflect the efficacy in people with MS 
 The efficacy of CD20 therapy in MS may be removal of the proposed aetiological agent Epstein-
Barr virus.  
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ABSTRACT 
 
MS is widely-considered to be a T cell-mediated disease although T cell immunotherapy has 
consistently failed, demonstrating distinct differences with experimental autoimmune 
encephalomyelitis (EAE) in which T cell therapies are effective. Accumulating evidence has 
highlighted that B cells also play key role in MS pathogenesis. The high frequency of oligoclonal 
antibodies in the CSF, the localization of immunoglobulin in brain lesions and pathogenicity of 
antibodies originally pointed to the pathogenic role of B cells as autoantibody producing plasma 
cells. However, emerging evidence reveal that B cells also act as antigen presenting cells, T cell 
activators and cytokine producers suggesting that the strong efficacy of anti-CD20 antibody therapy 
observed in people with MS may reduce disease progression by several different mechanisms. Here 
we review the evidence and mechanisms by which B cells contribute to disease in MS compared to 
findings in the EAE model.  
 
KEY WORDS: multiple sclerosis; animal models; experimental autoimmune  encephalomyelitis; 
therapeutics; B cells; CD20; Epstein-Barr virus 
 
ABBREVIATIONS: CNS - central nervous system; EAE - experimental autoimmune encephalomyelitis; 
MS - multiple sclerosis, PwMS - Person with MS, EBV - Epstein-Barr virus. 
 
1. INTRODUCTION 
Multiple sclerosis (MS) is a chronic immune-mediated neurodegenerative disease of the central 
nervous system (CNS) characterized by inflammation, demyelination and axonal loss. The most 
widely used model to study such CNS damage as well as for drug development for MS is 
experimental autoimmune encephalomyelitis (EAE) (Baxter 2007;  Gold et al., 2006, Kipp et al., 
2012). EAE is a spectrum of experimentally induced immune-mediated neurological diseases of the 
CNS (Kipp et al 2012), induced in many species. It is well known that the mode of induction, animal 
species and strains of rodents heavily influence the course of disease and observed immunological 
and pathology in the CNS (Kipp et al 2012, Baker and Amor 2013). Most current drugs available for 
MS are broad spectrum immunosuppressant/immunomodulatory agents, although in recent years 
more specific therapies using cell-depleting antibodies have been designed. Amongst the most 
successful of these antibody treatments are the B cell-targeted treatments  (Kappos et al. 2011; 
Brück et al., 2013). Despite the apparent efficacy of B cell depletion there is much to be learned 
about how B cells contribute to the regulation and pathogenesis of MS,  given the balance between 
B regulatory and B effector cell functions as shown both in animals and MS. In addition, broad B cell-
targeted depletion carries risks, notably associated infections. This indicates that despite being very 
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effective, the depletion regimen could be better targeted to remove pathogenic B cells while leaving 
the protective and regulatory arm intact. 
2. B CELLS AND AUTOANTIBODIES IN EAE  
Until the last decade MS has been widely-considered a white matter disorder, and thus EAE has 
been commonly induced following immunization with myelin antigen such as myelin basic protein 
(MBP). However, clinical and pathological features of MS are usually better represented when EAE is 
induced using total CNS tissues (Sospedra et al., 2005) suggesting  that autoimmunity to other 
myelin components may be essential to model chronic relapsing neurological disease, demyelination 
and axonal damage and secondary progressive disease. Currently, the most widely used autoantigen 
for induction of EAE is the minor protein myelin oligodendrocyte glycoprotein (MOG), which present 
on the outer membrane of oligodendrocytes (Schluesener et al., 1987, Linington et al., 1988; Amor 
et al., 1994). Similar to EAE induced with other autoantigens, the clinical course and pathology of 
MOG-induced EAE is heavily depend on the nature of the MOG antigen and mouse strain [Table 1].  
 
Table 1: Outcome of MOG-induced EAE in WT and B cell deficient mice  
Antigen Mutation or 
treatment 
EAE Course  Antibody or 
Bell 
requirement 
Reference 
(m)recMOG Biozzi ABH mice Chronic relapsing  Amor et al 1994 
Biozzi mice  +  
MOG antibodies 
Increased EAE severity 
Augmented demyelination  
Yes Morris-Downs et al 
2002 
(m)SCH Biozzi mice + 
Rituximab  
No effect on EAE No D Baker - 
Unpublished  
(m)MOG35-55 Biozzi ABH Monophasic chronic No Amor et al., 2005 
(m)recMOG WT  C57BL/6 Chronic EAE No Lyons et al.,1999 
 μMT C57BL/6 No EAE 
CD20+ cell 
depletion 
Not known   
(r)MOG WT  C57BL/6 Chronic EAE No Oliver et al., 2003 
 μMT C57BL/6 Chronic EAE 
CD20+ cell 
depletion  
Not known   
(h)recMOG  WT  C57BL/6 Chronic Yes Oliver et al., 2003 
μMT C57BL/6 No EAE 
B cell depletion Not known   
(m)MOG35-55 WT  C57BL/6 Chronic No Lyons et al., 1999 
Mouse specific 
CD20+ cell 
depletion 
Severe or reduced EAE 
depends on timing of CD20 
depletion 
Yes Matsushita et al., 
2008 
MOG - myelin oligodendrocyte glycoprotein, m – mouse; h – human; recMOG – recombinant MOG; WT – wild 
type;  μMT - Knock-out mice that lack functional B cells. 
 
Importantly, the majority of studies, including those focusing on the role of B cells, makes use of the 
C57BL/6 mice since most transgenic or mutant mice are bred on this background. Notably, the 
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majority of EAE studies in this mouse strain uses mouse MOG35-55 peptide. The disease is 
monophasic and B cells or  pathogenic antibodies to MOG do not play a role (Oliver et al 2003). Such 
pathogenicity of the protein is also influenced by the protein conformation as well as the presence 
of post translational modifications that may better reflect proteins in their native form in the myelin 
membranes (Smith et al 2005; de Graaf et al 2012).  
The role of pathogenic autoantibodies was indicated following the demonstration  that circulating 
autoantibodies to myelin in EAE induce myelin damage in vitro and in vivo (Apple and Borstein 
1964). This is supported by studies showing that titres of antibodies to myelin are high during 
chronic stages of EAE when demyelination was most pronounced, and that some MOG antibodies, 
notably those that fix complement, augment EAE (Linington et al., 1989, Morris-Downes et al., 2002; 
Piddlesden et al., 1993, Menon et al., 1997, Mead et al., 2002; Hundgeburth et al., 2013). In 
addition, MOG antibodies have functional effects on oligodendrocyte inducing stress, physiological 
and morphological changes (Duvanel et al., 2004; Marta et al., 2005) and have recently been shown 
to trigger T cell activation by opsonisation of endogenous antigen (Kinzel et al., 2016). It is clear that 
pathogenic antibodies, possibly secondarily to damage, are generated by MS (Willis et al. 2015) and 
can cause demyelination and pathology when injected in to animals (Linington et al., 1988, Morris-
Downes et al., 2002)). However, it appears that autoreactive T cells are necessary for the clinical 
disease to develop. It was shown in animals studies that T cells initiate the  blood-brain barrier 
disturbances that facilitate entry of B cells and immunoglobulins into the CNS. Once in the CNS 
autoantibodies bind to oligodendrocytes and myelin, activate complement and induce 
demyelination that subsequently enhances inflammation and increases EAE severity.  
 
3. B CELL AS IMMUNE MODULATORS  
Emerging evidence using B cell-deficient mice has revealed a much more complex role for B cells in 
antigen presentation, cytokine production and immune regulation of EAE [Figure 1]. While early 
studies showed that depletion of IgM from birth prevented B cell maturation and subsequent EAE 
induction (Willenborg and Prowse, 1983), recent evidence for B cells in EAE comes from studies 
using the MOG EAE model in C57BL/6 following genetic ablation and depletion using anti-CD20 
antibodies [Table 1]. These studies suggest that B cells are necessary for EAE induced with 
recombinant MOG protein but not MOG35-55 EAE, revealing the critical impact of the source and 
nature of immunogens (Weber et al. 2010). This difference in EAE induction can be explained by the 
role of B cells to differentially present MOG protein and peptide (Weber et al., 2010). While genetic 
ablation of MHC class II antigens on B cells abrogates antigen presentation of MOG to T cells and 
thus inhibits EAE induction (Molnarfi et al., 2013), antigen presentation by B cells and thus EAE 
induction requires dendritic cells (Parker et al 2015).  Next to the requirement of MHC class II 
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antigen expression of T cell costimulatory molecules expressed by B cells, such as CD80/CD86 and 
CD40, also plays a crucial role in EAE (Mann et al., 2007; Ray et al., 2011). While mice (in this case 
B10.PL) in which B cells lack co-stimulatory CD80/CD86 molecules develop EAE, they fail to recover 
due to a delay in IL-10 production and mobilization of Foxp3 regulatory T cells (Mann et al., 2007). In 
addition, B cells produce pro-inflammatory and anti-inflammatory cytokines that impact on EAE 
(Molnarfi et al., 2013) [Table 2].  
 
Table 2. B cell production of cytokines during EAE 
Cytokine Produced via Effect mechanism Effect on EAE Reference 
LT1α2β FDCs and 
CXCL13 
Follicle formation Increased 
inflammation 
Magliozzi et al.,2004, 
2007 
TNF LT1α2β Increased IFN-γ and 
inflammation 
Increased severity Menrad et al.,2007, 
Matejuk et al.,2002 
IL-6 Innate 
receptors 
Increased ICAM and 
VCAM expression. 
Increased T cell 
infiltration  
Increased severity Okuda et al,1998, 
Eugster et al,1998  
 
IL-10 CD40 and B7 Increased Tregs, 
decreased inflammation 
Reduced severity Bettelli et al.,1998, 
Fillatreau et al.,2002 
Matsushita 2008 
IL-35 TLR4 and 
CD40 
Decreased APC function Reduced severity Shen et el.,2014 
Abbreviations: APC – antigen presenting cell; IL – Interleukin; Tregs – regulatory T cells, TLR - Toll-
Like receptor, FDCs - Follicular Dendritic Cells, CXCL13 - Chemokine CXC-motif Ligand 13,  
 
B cells secrete lymphotoxin α1-β2 (LTα1β2) essential for lymph node expansion and development of 
tertiary lymphoid tissue, which are sometimes present in the CNS during EAE (Lassmann et al., 
2011). LTα1β2 is observed in the CNS during EAE in SJL mice (Magliozzi et al., 2004, Columba-
Cabezas et al., 2006) and clinical disease is prevented with antibodies to LTα1β2 receptor, due to 
inhibition of CXCL13 important for lymphoid follicle development (Columba-Cabezas et al., 2006). 
Antigen activated B cells also produce TNF, a key cytokine in EAE (Matejuk et al., 2002).  Another B 
cell-derived cytokine is interleukin-6 (IL-6), it is increased during EAE and has an impact on EAE 
pathogenesis (Barr et al., 2012). A mechanism by which IL-6 may contribute to MS pathogenesis is by 
regulating  T cell infiltration into the CNS since expression of ICAM-1 and VCAM-1 are absent in IL-6 
deficient mice (Eugster et al., 1998). Additionally, B cells also produce IL-10 as well as IL-35; 
cytokines that reduce EAE severity. Such regulatory B cells (Bregs) from mice in EAE remission, 
produce IL-10 in a CD40 dependent manner and transfer of these Bregs into mice with EAE induces 
recovery (Fillatreau et al., 2002). Thus, IL-10 producing Bregs are important for disease recovery. 
Furthermore, IL-10-producing B cells play an important role in EAE initiation by down-regulating the 
conditions leading to T cell CNS infiltration (Matsushita et al., 2008, 2010). Finally, IL-35 producing B 
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cells also control EAE severity since mice lacking these B cells develop exacerbated EAE. IL-35 
regulates APC functions of B cell that together with IL-10 induces differentiation of plasma cells. 
Mice in which B cells lack IL-35 have stronger antigen presentation capabilities, this is associated 
with stronger inflammatory responses and more severe EAE (Shen et al., 2014). 
 
4.  B CELLS AND AUTOANTIBODIES IN MS  
B cells, plasma cells, plasmablasts and antibodies directed to oligodendrocytes, myelin and neurons 
are detectable in peripheral blood and the cerebrospinal fluid (CSF) of people with MS (pwMS) 
(Olsson et al., 1990; van Noort et al., 2006; Amor et al., 2014 ). In the CSF oligoclonal IgG bands 
(OCBs), present in 95% pwMS, are an established diagnostic tool for MS. That some 
immunoglobulins may play a role in disease is reflected by the close associate of lesions to CSF flow, 
such as ventricular and subpial lesions and that OCB-negative patients are characterized by less 
global and regional brain atrophy (Ferreira et al 2014). Further supports comes from the study 
showing that clonally expanded plasma cells from the CSF induce myelin damage in vitro, thus 
implicating intrathecal IgG in MS pathogenesis (Blauth et al., 2015). In addition the CNS 
immunoglobulins and complement deposits are present on disintegrated myelin sheath and 
demyelinating lesions (Raine et al., 1999, Lucchinetti et al., 2000; Storch et al., 1998), indicating that 
like EAE CNS reactive antibodies mediate demyelination and neuronal damage [Figure 2]; findings 
that have been confirmed in vitro studies (Zhou et al., 2006; Blauth et al., 2015). In addition, the 
finding of B cell follicle-like structures as well as chemokines and cytokines that support B cell 
development all provide support for a key role of B cells, plasma cells and autoantibodies in MS 
pathogenesis. Like EAE, B cells extracted from pwMS and stimulation with CD40L and IL-4 have been 
shown to present myelin specific antigens to autoreactive T cells (Harp et al., 2008) indicating that B 
cells have the capacity for antigen presentation in MS also. 
In support of a role of B cells in MS, B cell follicles have been reported in the meninges of people 
with secondary progressive MS (pwSPMS; Serafini et al., 2004), although this is controversial since 
follicles are not present in all pwSPMS and MS cohorts (Peferoen et al 2007). In pwMS in which 
follicles are observed the presence of the ectopic follicles were more pronounced in pwMS showing 
earlier clinical symptoms and earlier death than the negative group (Magliozzi et al., 2007). The 
number of these B cells characterized by up regulated chemokine receptors to CXCL13 (Corcione et 
al., 2004) were significantly higher in the CSF as compared to blood. Together with LT1α2β, CXCL13 
has been found in the CSF and MS brain tissue in active lesions (Corcione et al., 2004, Krumholz et 
al., 2006) and may thus contribute to disease severity by aiding inflammation. In support of this, B 
cell follicles and meningeal infiltrates have been associated with cortical grey matter lesions widely 
considered to contribute to cognitive decline in MS (Magliozzi et al., 2007). How these follicles arise 
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is as yet unknown, although several studies suggest strong association with EBV widely considered to 
be an aetiological agent in MS.  
There is also clinical evidence for regulatory B cell functions in MS (Fillatreau et al., 2002, Shen et al., 
2014). Recently a subset of IL-10 producing B cells has been identified in blood of healthy controls 
and pwMS (Iwata et al., 2011) in which production  is lower in pwMS and then restored or increased 
via therapy (Ozenci et al., 2000). As in rodents production of IL-10 in human B cells increases 
following treatment with CD40L, lipopolysaccharide (LPS) or CpG. Together the gathered data on the 
role for B cells in MS and EAE demonstrates its involvement in antigen presentation, cytokine 
production and T cell activation. This abundant evidence demonstrates that the role of B cells in MS 
pathology is not merely antibody production. Therefore targeting B cell in the treatment of MS has 
been a rational approach towards improving the MS pathology.  
 
5. B CELL THERAPIES  
Many current therapies for MS also inhibit or modify B cell function. For example the cytostatic 
agents mitoxantrone, cyclophosphamide preferentially kill B cells due to their high basal 
proliferation rate (Fox 2004), alemtuzumab depletes T and B cells (Ruck et al 2015) and glatiramer 
acetate reduces B cells numbers in subset of pwMS (Rovituso et al 2015). Likewise, fingolimod 
decreases memory B cells but increases naive B cells (Claes et al 2014) while dimethyl fumarate is 
reported to also reduce B cells numbers (Spencer et al 2015). In contrast, natalizumab increases 
circulating B cells while IFN-β treatment increases CD19, CD24, CD38 B cells in peripheral blood, 
although whether B cells in the CNS are affected has not been reported. Cladribine is a highly 
effective depleting agent of peripheral B cells, compared to T cells (Mitosek-Szewczyk et al 2013) and 
through targeting dividing and non-dividing lymphocytes inhibits lesion formation in both relapsing 
MS and progressive MS (Rice et al 2000; Giovannoni et al. 2010). It is the only MS disease-modifying 
agent that is CNS penetrant, with an immunomodulatory action that is active in the CNS, which has 
the capacity to target plasma cells and can inhibit oligoclonal band protein formation (Sipe et al. 
1994). Whilst efficacy in relapsing MS has been reported (Giovannoni et al., 2010), trials in 
progressive MS were too short to determine efficacy in progression (Rice et al. 2000). Unfortunately, 
due to probably unfounded concerns on safety, oral cladribine was withdrawn (Pakpoor et al., 2015). 
In summary, although studies clearly reveal  the multifunctional roles of B cells in MS several 
therapeutic approaches can be applied to modulate B cell functions.  
 
5.1 CD20 targeted therapy 
Three anti-CD20 antibodies rituximab, a chimeric human/mouse IgG1 antibody; ocrelizumab, a 
humanized antibody, and ofatumumab, a full recombinant human IgG1 antibody have been used in 
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clinical trials for MS (Hauser et al. 2008; Kappos et al. 2011; Sorensen et al. 2014). All antibodies 
deplete cells expressing CD20, a surface antigen present on maturating B cells, from pre-B cells to 
plasmablasts, precursors of plasma cells [Figure 3], as well as a population of T cells. The first study 
of rituximab, conducted in 5 people with primary progressive MS (pwPPMS), showed that most 
peripheral blood B cells were depleted until 14 months (Monson et al., 2005). The depletion of CSF B 
cells was less efficient. A phase I open study, designed to assess the drug safety and tolerability in 
RRMS did not reveal serious adverse effects (Bar-Or et al.,2008). Clinical trials that followed showed 
that B cell depletion effectively suppressed MS disease activity (Hauser et al., 2008, Hawker et al., 
2009, Kappos et al., 2011). In a double-blind placebo-controlled phase II trial, Rituximab reduced 
newly formed CNS lesions and relapses in relapsing remitting MS (RRMS) (Hauser et al., 2008). 
Studies with ocrelizumab, reduced gadolinium-enhancing lesions in RRMS by 89% compared to 
placebo and Interferon β (Kappos et al., 2011) and inhibited relapsing MS and lesion formation in 
phase III trails (Hauser et al. 2015). Ocrelizumab has shown some positive results in PPMS in the 
phase III  trial (Montalban et al. 2015). Here, the study focused on younger people with active 
disease and closer to progressive onset of MS, based on the responder profile of an earlier trial in 
PPMS with rituximab (Hawker et al. 2009). Lastly, ofatumumab, an approved drug for chronic 
lymphocytic leukemia is expected to be far less antigenic than rituximab. This was exmained in 
RRMS, revealing a greater than 99% reduction in newly formed lesions in RRMS compared to 
controls.  No increase in adverse effects was noticed in treated compared to controls (Sorensen et 
al., 2014). While CD20 targeting therapies reduce MS lesions and clinical relapses the 
immunoglobulin levels are not significantly affected (Hauser et al., 2008), not surprisingly since 
plasma cells do not express CD20 and are therefore not depleted. This suggests that CD20+ cell 
depletion interferes with antigen presentation, T cell activation or cytokine production [Figure 4]. 
The preclinical findings in EAE showing that B cells polarize T cell differentiation were confirmed in 
pwRRMS treated with anti-CD20 antibody treatment, emphasizing the APC function of B cells in 
RRMS (Bar-Or et al.,2010). The number of CSF T cells also decreased following treatment in the 
majority of RRMS patients (Cross et al., 2006).  
 
5.2 CD20+ T cells 
In addition to the effect on B cell function and thereby indirectly affecting T cells, emerging evidence 
shows that anti-CD20 antibody therapy also directly affect CD20+ T cells. Interestingly, evidence for 
the direct T cell effect was suggested in early Rituximab studies for treatment of rheumatoid arthritis 
(Wilk et al., 2009) who also reported CD20+ T cells in peripheral blood of healthy people and those 
with rheumatoid arthritis (Wilk et al., 2009). CD20+ cells comprise both CD8 and CD4 T cell subtypes 
and are depleted with CD20+ B cells during Rituximab therapy (Wilk et al., 2009).  Data from RRMS 
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supports the presence of CD20+ T cells in the peripheral blood and CSF in pwMS (Palanichamy et al., 
2014) and cerebral subventricle white matter samples (Holley et al., 2014). Since CD20 expression is 
lower on CSF T cells was less noticeable, they were characterized as CD20dim T cells that are both 
CD8+ and CD4+. Interestingly, CD20-specific antibody predominantly depleted CD8+ CD20dimT cells 
although the overall CD4/CD8 ratio remained unchanged (Palanichamy et al., 2014). In the CNS, 
particularly in active MS lesions, T cells are CD20high and express IL-17 and IFN-γ indicating a more 
pro-inflammatory profile (Holley et al., 2014) suggesting that CD20-specific immunotherapy may 
thus modify disease by directly depleting inflammatory CD20high/dim T cells.  Furthermore,, it was 
demonstrated that rituximab/anti-human CD20 had most efficacy in controlling EAE in human CD20 
transgenic mice when antibody treatment induced marked T cell depletion (Weber et al. 2010). 
 
5.3 Risks of Infection 
Due to the broad B cell target, anti-CD20 antibodies also deplete B cells that regulate immune 
responses including those controlling viruses. Incidental cases of progressive multifocal 
leukoencephalopathy (PML) in people treated with rituximab with other immune disorders have 
been observed (Clifford et al 2011), which suggests a risk of PML development in MS. Furthermore, 
ocrelizumab development in rheumatoid arthritis and systemic lupus erythematosus was halted 
because it was linked to serious life-threatening infections (Tak et al 2012). However, development 
of B cell depletion has a better risk:benefit profile in MS, because of the poor prognosis of MS. 
Whilst it has similar levels of efficacy to alemtuzumab in relapsing MS (Cohen et al. 2012; Kappos et 
al. 2011), it does not cause the high incidence of secondary B cell autoimmunities following 
treatment with alemtuzumab (Cohen et al. 2012, Tuohy et al. 2015) thus making it an attractive new 
treatment for MS.  
 
6. Novel B cell targeting therapies 
Anti-CD19 therapy, being developed for neuromyelitis optica has been suggested  as a new 
treatment for MS target  B cells including plasma blasts and short-lived plasma cells (Stüve et 
al.,2014), thereby reducing the levels of pathogenic antibodies (Stüve et al.,2014). MEDI-551, a 
humanized anti-CD19 IgG1 antibody has been reported to reduce lesions in RRMS (Aguis et al. 2015). 
The humanized antibody is able to bind and deplete a broader range of B cells but its working 
mechanism of depletion is similar to that of anti-CD20. In a humanized CD19 B cell animal model, 
anti-CD19 treatment could reduce antibody levels because of its ability to deplete plasma blasts 
(Yazawa et al., 2005). In a CD19 and CD20 transgenic animal model, MEDI-551 more efficiently 
depletes B cells by depleting pro-B cells, delaying B cell renewal (Herbst et al.,2010). However such 
approaches might lead to more adverse events such as PML or opportunistic infections. VAY736, is 
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directed against the B-cell activating factor receptor (BAFF-R) designed to reduce the B cell fostering 
milieu in the CNS (Kumbholz et al., 2005, Magliozzi et al., 2004). Upon binding to its receptor, BAFF 
aids B cell survival but it is also involved in B cell development and B cell mediated meningeal follicle 
formation (Magliozzi et al., 2004). Since BAFF is elevated in MS, targeting the BAFF-R prevents its 
binding to take place thereby reducing B cell survival and lymphoid follicle-like structures. BAFF-R 
deficient mice with EAE had fewer mature B cells and increased EAE severity, suggesting a 
predominant effect on Breg (Sasaki et al., 2004, Kim et al., 2011). Similarly increased disease severity 
was also shown with atacicepet, a B BAFF-immunoglobulin fusion protein that targets BAFF receptor 
and A ProlifeRation-Inducing ligand (APRIL). The study was halted after increased inflammatory 
activity was observed in pwRRMS (Hartung et al., 2010) demonstrating that B cell depletion is not 
universally a predictable and positive therapeutic effect, as was shown in initial studies in EAE, when 
B cell depletion could inhibit, do nothing or augment  disease (Matsushita et al. 2008).  
Active RR- and PPMS is inhibited by peripheral B cell depletion with CD20-depleting antibodies, 
which may also be active in the CNS due to blood-brain barrier disturbances (Bonnan et al. 2014, 
Hauser et al. 2015; Montalban et al. 2015). The thought that central B cell activity my drive 
progressive MS has led to the idea of targeting B cells via local administration (Bonnan et al. 2014; 
Svenningsson et al. 2015). Yet, intrathecal administration fails to induce marked B cell depletion 
within the CNS and simply drains from the natural flow of CSF into the circulation and depletes 
peripheral B cells (Komori et al. 2016, Topping et al. 2016). Therefore, it remains to be established 
whether intraventricular CD20 B cell depletion would have merit in targeting CNS-B cells or whether 
novel plasma cell depleting antibodies (Moreau et al. 2014) will be necessary to target ectopic B cell 
follicles in the CNS.  
  
7. Future perspectives and concluding remarks 
Immunodepleting agents, especially if used early after diagnosis, can induce long-term No-evidence 
of Disease Activity (NEDA; Giovannoni et al. 2015) in MS (Tuohy et al. 2015). For many years MS has 
been thought to be a T cell mediated disease, largely due to similarities with EAE (Baker & Amor 
2014). With the knowledge that antibodies and B cells play a significant role in MS, B cell targeted 
therapies have been developed and have been found to have marked inhibitory activity on active 
MS. Success in treating relapsing and progressive MS by B cell therapy, has been hailed as the 
beginning of the end of the neurodegeneration of progressive MS (Steinman and Zamvil 2016), 
however this remains to be established especially as inhibiting peripheral autoimmunity does not 
appear to stop EAE (Al-Izki et al. 2011) or MS following haematopoitic stem cell therapy (Burt et al. 
2015). Even though there has been much focus on T cell autoimmunity in MS, it is clear that the 
highly effective agents can target B cells.  Although the aetiology of MS is unknown, it is clear that 
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genetics and environmental factors contribute to susceptibility to MS. One consistent feature of MS 
is the potential role of Epstein-Barr virus (EBV) as a trigger of disease activity (Pakpoor et al. 2013). 
Given that EBV readily infects B cells another mechanism by which B cell depletion may operate 
removal of this aetiological trigger of relapsing MS (Pakpoor et al. 2013). 
It is clear that broad B cell targeted depletion carries risks, notably associated with risks of infection. 
However, compared to drugs of similar efficacy such as natalizumab and alemtuzumab the adverse 
events may even be favourable.  Yet, there is much to be learned about how B cells contribute to the 
regulation and pathogenesis of autoimmunity given the balance between B regulatory and B effector 
cell functions as shown EAE and MS. Irrespective of this it appears that depletion of CD20+ B cells 
offers promise as a disease modifying therapy of MS and it will probably gain approval for treatment 
of MS.   
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Legends 
Figure 1.  The multifunctional roles of B cells in EAE and MS. A) B cells act as antigen presenting 
cells that activate autoreactive T cells.  B) B cells mature to plasma cells that produce antibodies 
including CNS reactive autoantigens. C ) Mature B cells process antigens, and once activated produce 
pro- and anti-inflammatory cytokines important in (D) the development of tertiary lymphoid tissue. 
E) B cells also harbor Epstein-Barr Virus (EBV) thought to a key aetiological agent in MS. 
 
Figure 2. Antibody functions in MS and EAE. The primary effect of pathogenic antibodies  is 
induction of tissue damage.  Anti-myelin antibodies produced by plasma cells (1) attach to myelin 
leading to opsonisation (2). Macrophages bearing FcR bind to antibody on myelin (3).  Alternatively, 
macrophages bind immunoglobulin via FcR receptors (4) that then bind to myelin inducing antibody 
dependent cell mediate cytoxicity. Antibodies on myelin (5) trigger complement activation leading to 
the formation of membrane attack complex (MAC) and cell death (6).  
 
Figure 3. B cell development. CD19 is highly expressed throughout B cell development but not on 
terminally differentiated plasma cells. CD20 is expressed on the majority of B cell subtypes but is 
down-regulated in plasmablasts. B cell activating factor receptor (BAFF-R) is expressed later in 
development from immature B cells to plasmablasts.  
 
Figure 4. Effect of anti-CD20 antibody in MS. Anti-CD20 antibody binds to and depletes CD20+ cells, 
including CD20+ pro-inflammatory CD4 and CD8 cells, involved in CNS inflammation and 
demyelination.  
Reg B - Regulatory B cells, Mφ - Macrophage CTL: Cytotoxic T cell 
 
 
